Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sarpogrelate

Known as: 2-(dimethylamino)-1-((2-(3-methoxyphenyl)phenoxy)methyl)ethyl hydrogensuccinate hydrochloride, mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride 
 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Fibrinolytic AgentsPlatelet Aggregation InhibitorsSerotonin AntagonistsSuccinates

Narrower (1)

MCI 9042

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial
Background and Purpose— The antiplatelet agent sarpogrelate is a selective inhibitor of 5-hydroxytryptamine receptors. The… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2007
Highly Cited
2007
Sarpogrelate Hydrochloride, a Selective 5-HT2A Antagonist, Improves Vascular Function in Patients With Peripheral Arterial Disease
Peripheral arterial disease (PAD) is 1 of the major manifestations of atherosclerosis. PAD is associated with endothelial… Expand
Review
2004
Review
2004
Therapeutic potentials of sarpogrelate in cardiovascular disease.
In view of the pivotal role of serotonin (5-HT) in a wide variety of cardiovascular disorders, extensive effort has been made to… Expand
Highly Cited
2003
Highly Cited
2003
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Although sarpogrelate HCl is widely used for the prevention of arterial thrombosis, its effect on atherosclerosis is unknown… Expand
Highly Cited
2003
Highly Cited
2003
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
The aim of the present study was to investigate the binding sites interactions and the selectivity of sarpogrelate to human 5-HT… Expand
2003
2003
Sarpogrelate treatment reduces restenosis after coronary stenting.
BACKGROUND Sarpogrelate, a serotonin blocker, has been reported to inhibit the serotonin-induced proliferation of rat aortic… Expand
2002
2002
Binding and Functional Affinity of Sarpogrelate, Its Metabolite M-1 and Ketanserin for Human Recombinant Alpha-1-Adrenoceptor Subtypes
Serotonin (5-HT2) antagonists show high affinity for the α1-adrenoceptor (α1-AR) in addition to the 5-HT2 receptor. In the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2000
2000
Antinociception in rat by sarpogrelate, a selective 5-HT(2A) receptor antagonist, is peripheral.
The antinociceptive effect of sarpogrelate, a new selective 5-hydroxytriptamine (5-HT)(2A) receptor antagonist, in the formalin… Expand
Highly Cited
2000
Highly Cited
2000
Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model.
Serotonin is one of the most important vasoactive substances and has been implicated in the pathogenesis of coronary artery spasm… Expand
Highly Cited
1999
Highly Cited
1999
Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate.
Antiproliferative behavior of sarpogrelate (Anplag, MCI-9042, (+/-)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-3-(dimethylamino)-2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE